
|Videos|August 26, 2021
Part 1: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML
Alexandra S. Wolff, PharmD, BCOP, discusses use of IDH1 and IDH2 inhibitors in newly diagnosed AML patients and highlights recently released trial data.
Advertisement
Episodes in this series

Advertisement
Related to this article

A transplant pharmacist looks at what azacitidine plus venetoclax’s event-free survival advantage over intensive chemotherapy means for induction selection, and why it doesn’t yet replace 7+3 or CPX-351.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Two-Drug HIV Regimens, Archived M184V Resistance, and Long-Acting Preference
2
Long-Acting HIV Injectables in Viremia and New Tenofovir-Free Oral Options
3
SNO 2026 Roundup: What Longer Follow-Up Means for Targeted Glioma Care
4
Overton FDA Nomination Withdrawn: What It Means for Pharmacists
5
